Freenome (NASDAQ:FRNM) Upgraded to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Freenome (NASDAQ:FRNM) to a strong-buy rating in a report released on Monday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. BTIG Research initiated coverage on Freenome in a research note on Monday. They issued a “buy” rating and a $17.00 price target on the stock. TD Cowen assumed coverage on shares of Freenome in a research note on Tuesday. They set a “buy” rating for the company. Finally, Leerink Partners initiated coverage on shares of Freenome in a research note on Friday. They issued an “outperform” rating and a $18.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, Freenome has an average rating of “Strong Buy” and a consensus target price of $17.33.

Freenome Stock Up 12.5%

FRNM stock opened at $13.00 on Monday. The firm has a market cap of $106.08 million, a price-to-earnings ratio of -216.63 and a beta of 0.35. Freenome has a 52-week low of $9.97 and a 52-week high of $14.26.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.